Alfonso J. Tafur: New Biomarkers Transform Pulmonary Embolism Risk Prediction
Alfonso J. Tafur, Board Member VAS European Independent Foundation in Angiology and Vasculearn Network, shared RPTH Journal’s post on LinedIn about a recent article he and his colleagues co-authored, adding:
“Proud to be a co-author on this important publication led by Fakiha Siddiqui Congratulations
This study moves beyond traditional clinical risk scores by showing that thromboin flammation and hemostatic activation are major drivers of early mortality in acute PE. Among the most clinically relevant findings:
- Neutrophil-to-lymphocyte ratio (NLR) above 7 emerged as one of the strongest and most accessible predictors of 30-day mortality.
- Combining NLR, PAI-1, and TNF-α identified a subgroup with markedly higher mortality, highlighting the value of integrated biomarker assessment.
- The work supports incorporating biologic markers of inflammation, endothelial injury, coagulation, and fibrinolysis into future PE risk stratification models. Precision Medicine
Excited to see how these findings help shape the next generation of personalized pulmonary embolism care.”
RPTH Journal shared a post on LinkedIn:
“Pulmonary embolism mortality: can thromboinflammation biomarkers do better than current scoring systems?
Despite advances in diagnosis and treatment, pulmonary embolism (PE) still carries significant mortality, and current prognostic models remain poorly predictive of who will deteriorate. A new study in RPTH Journal takes a comprehensive biomarker approach to address this gap.
Key findings from 500 patients with PE (9.7% died within 30 days):
- Levels of vWF, P-selectin, tissue factor, tPA, PAI-1, D-dimer, CRP, IL-6, TNF-α, NLR, PLR, and SII were significantly higher in 30-day non-survivors
- FVII, FX, FXIIIA, and TAFI levels were significantly lower in non-survivors
- Multivariable analysis confirmed independent associations between these markers and 30-day mortality
- CHAID recursive partitioning identified NLR, PAI-1, and TNF-α as the key mortality predictors, with quantifiable thresholds established for each.”
Title: Thromboinflammation and hemostatic activation drive early mortality risk in pulmonary embolism
Authors: Fakiha Siddiqui, Alfonso Tafur, Amir Darki, Bulent Kantarcioglu, Debra Hoppensteadt, Jeanine Walenga, Manuel Monreal, Jawed Fareed
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 4, 2026, 18:57Connecting Haemophilia Centres, Certifying Treaters, and Improving National Data in Romania – EHC
-
Nov 4, 2026, 18:45Smitirupa Mishra: A Practical Guide to Coagulation Pathway Assessment and Laboratory Interpretation
-
Nov 4, 2026, 15:59Alessandra Bosch: A Successful Patient Day for the Bleeding Disorders Community in Zürich
-
Nov 4, 2026, 15:47Wolfgang Miesbach: Targeting Hepatic Endothelial Cells for Lentiviral Gene Therapy in Haemophilia A
-
Nov 4, 2026, 15:20Augustina Isioma Ikusemoro: Before You Transfuse, Think PBM
-
Nov 4, 2026, 14:23Advancing Hemophilia Care Through Global Research – WFH
-
Nov 4, 2026, 14:12Jean-Jacques Kiladjian: From JAK Inhibitor-Associated Skin Cancers to Laboratory Discovery
-
Nov 4, 2026, 13:59Rita Li: ASH 2026 Abstract Achievement Award for Gut Microbiome Research
-
Nov 4, 2026, 13:38Omid Seidizadeh: Improving Access to von Willebrand Disease Diagnosis and Treatment Across Europe